Ginkgo Competitors
| DNA Stock | USD 10.15 0.05 0.50% |
Ginkgo Bioworks vs Valneva SE Correlation
Weak diversification
The correlation between Ginkgo Bioworks Holdings and VALN is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ginkgo Bioworks Holdings and VALN in the same portfolio, assuming nothing else is changed.
Moving against Ginkgo Stock
As of February 11, 2026, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.53. At present, Ginkgo Bioworks' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 27.1 M, whereas Net Tangible Assets are forecasted to decline to about 1.1 B.Ginkgo Bioworks Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ginkgo Bioworks and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ginkgo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ginkgo Bioworks Holdings does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ginkgo Stock performing well and Ginkgo Bioworks Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ginkgo Bioworks' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | 4.27 | 0.67 | 0.14 | 1.65 | 4.02 | 11.81 | 37.34 | |||
| REPL | 2.61 | (0.18) | 0.00 | (0.08) | 0.00 | 5.56 | 14.00 | |||
| MBX | 4.24 | 0.93 | 0.19 | 42.87 | 3.93 | 14.40 | 29.11 | |||
| MGTX | 2.61 | (0.30) | 0.00 | (0.09) | 0.00 | 5.08 | 16.37 | |||
| AVBP | 2.88 | 0.20 | 0.06 | 0.32 | 2.94 | 6.71 | 18.12 | |||
| MRVI | 2.92 | 0.07 | 0.03 | 0.13 | 3.57 | 8.38 | 22.00 | |||
| ATXS | 0.85 | 0.06 | (0.01) | 0.59 | 1.00 | 2.11 | 6.54 | |||
| VIR | 3.38 | 0.45 | 0.13 | 0.35 | 3.40 | 8.08 | 23.40 | |||
| ARVN | 3.06 | 0.56 | 0.15 | 1.52 | 3.10 | 5.91 | 28.90 | |||
| VALN | 2.35 | 0.08 | 0.03 | 0.16 | 2.36 | 5.40 | 15.59 |
Cross Equities Net Income Analysis
Compare Ginkgo Bioworks Holdings and related stocks such as Iovance Biotherapeutics, Replimune Group, and MBX Biosciences Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOVA | (57.1 K) | (25.7 M) | (3.3 M) | (25.4 M) | (12 M) | (27.7 M) | (52.9 M) | (92.1 M) | (123.6 M) | (187.1 M) | (259.6 M) | (327.8 M) | (389.9 M) | (444 M) | (372.2 M) | (335 M) | (318.2 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| MBX | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (32.6 M) | (61.9 M) | (55.7 M) | (58.5 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| MRVI | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (8.5 M) | 76.9 M | 182 M | 220.2 M | (119 M) | (144.8 M) | (130.4 M) | (123.8 M) |
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.9 M) | (32.6 M) | (36.1 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.1 M) | (194.9 M) | (50.2 M) | (72.9 M) | (94.3 M) | (84.8 M) | (80.6 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (615.1 M) | (522 M) | (469.8 M) | (446.3 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
Ginkgo Bioworks Holdings and related stocks such as Iovance Biotherapeutics, Replimune Group, and MBX Biosciences Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ginkgo Bioworks Holdings financial statement analysis. It represents the amount of money remaining after all of Ginkgo Bioworks Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ginkgo Bioworks Competitive Analysis
The better you understand Ginkgo Bioworks competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ginkgo Bioworks' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ginkgo Bioworks' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Ginkgo Bioworks Competition Performance Charts
Five steps to successful analysis of Ginkgo Bioworks Competition
Ginkgo Bioworks' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ginkgo Bioworks Holdings in relation to its competition. Ginkgo Bioworks' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Ginkgo Bioworks in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ginkgo Bioworks' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ginkgo Bioworks Holdings, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Ginkgo Bioworks position
In addition to having Ginkgo Bioworks in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ginkgo Bioworks Correlation with its peers. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ginkgo Bioworks. Projected growth potential of Ginkgo fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Ginkgo Bioworks assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.18) | Revenue Per Share | Quarterly Revenue Growth (0.56) | Return On Assets | Return On Equity |
Understanding Ginkgo Bioworks Holdings requires distinguishing between market price and book value, where the latter reflects Ginkgo's accounting equity. The concept of intrinsic value - what Ginkgo Bioworks' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Ginkgo Bioworks' price substantially above or below its fundamental value.
It's important to distinguish between Ginkgo Bioworks' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ginkgo Bioworks should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Ginkgo Bioworks' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.